GSK reported a 7% increase in total sales for the full year 2025, reaching £32.7 billion compared to £30.5 billion in 2024. The Specialty Medicines segment was the primary growth driver, delivering 17% expansion to £13.5 billion. Within Specialty Medicines, the HIV portfolio grew 12%, Oncology rose 15%, and Respiratory, Immunology & Inflammation advanced by 18%, each contributing double-digit gains. The Consumer Healthcare division also posted moderate growth of 4%, supported by new product launches in core markets.

Following the robust full-year performance, GSK reaffirmed its 2026 revenue and margin guidance, projecting mid-single-digit top-line growth and continued margin expansion. The board approved a 5% increase in the annual dividend, taking the payout to 82p per share, to be paid in two equal installments. Management highlighted continued investment in R&D, with planned spending of approximately £5.5 billion in 2026, focused on late-stage assets in immuno-oncology and respiratory therapy areas.